Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
Kaan Harmankaya, Christa Erasim, Claus Koelblinger et al. · Medical Oncology · 2010
Cited by 107 works. doi:10.1007/s12032-010-9606-0
Authors
- Kaan Harmankaya
- Christa Erasim
- Claus Koelblinger
- Ramy A. Ibrahim
- Axel Hoos
- Hubert Pehamberger
- Michael Binder
References
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
- Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal Cancer
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- Current systemic therapy for metastatic melanoma